BioCentury
ARTICLE | Deals

Rigel’s decision tree behind its RIPK1 Lilly deal 

The $125M up front will fuel development of the early stage IRAK program that Rigel has opted to keep

February 19, 2021 12:51 AM UTC

Rigel’s deal with Lilly for its clinical RIPK1 program will triple the biotech’s cash balance as it seeks to expand the label of its sole marketed product while also developing a wholly owned, earlier-stage clinical candidate.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) will receive $125 million up front as Eli Lilly and Co. (NYSE:LLY) gains exclusive, worldwide rights to RIPK1 inhibitors including oral systemic therapy R552, which has completed a Phase I trial for inflammatory diseases...